Values as of: 2024-10-30
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 15.83Change
-0.09 (-0.57)%Market Cap
USD 4.39BVolume
0.66MAnalyst Target
N/AVerdict
Verdict
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Company Website : https://soterahealth.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| IDXX | IDEXX Laboratories Inc |
+3.25 (+0.73%) |
USD 37.69B |
| ICLR | ICON PLC |
-4.51 (-1.94%) |
USD 23.48B |
| ILMN | Illumina Inc |
+1.66 (+1.14%) |
USD 22.77B |
| NTRA | Natera Inc |
+1.99 (+1.60%) |
USD 14.84B |
| EXAS | EXACT Sciences Corporation |
+0.82 (+1.18%) |
USD 12.84B |
| MEDP | Medpace Holdings Inc |
-11.41 (-3.46%) |
USD 10.15B |
| RDNT | RadNet Inc |
-0.94 (-1.39%) |
USD 4.95B |
| NEOG | Neogen Corporation |
+0.23 (+1.60%) |
USD 2.98B |
| GH | Guardant Health Inc |
+1.28 (+5.87%) |
USD 2.52B |
| VCYT | Veracyte Inc |
+0.62 (+1.80%) |
USD 2.50B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| UKPH:XETRA | iShares UK Property UCITS.. | 3.70 % | 0.00 % |
+0.01 (+0.20%) |
N/A |
| IUKP:SW | iShares UK Property UCITS.. | 3.66 % | 0.00 % |
-0.01 (0.20%) |
USD 0.60B |
| Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -6.05% | 46% | F | 37% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -6.05% | 46% | F | 39% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 23.00% | 56% | F | 56% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 23.00% | 56% | F | 57% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -7.95% | 40% | F | 25% | F | ||
| Dividend Return | -7.95% | 40% | F | 24% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 35.62% | 82% | B | 52% | F | ||
| Risk Adjusted Return | -22.31% | 34% | F | 24% | F | ||
| Market Capitalization | 4.39B | 84% | B | 87% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
